Rybelsus Now OK'd in First Line; Menopause Before Transition; Novel T2D Drug Flops

Oral semaglutide (Rybelsus) received an expanded label to include first-line treatment for adults with type 2 diabetes as an adjunct to diet and exercise, Novo Nordisk announced.

The Obesity Society and Obesity Action Coalition lent support to the American Academy of Pediatrics' new childhood obesity guidelines in a statement, emphasizing that pediatric obesity is a disease and that early intervention is key.

In people with type 2 diabetes, using an SGLT2 inhibitor was linked with a 35% lower risk for incident obstructive airway disease compared with use of a DPP-4 inhibitor. (JAMA Network Open)

Even before the menopause transition starts, women in their late-reproductive stage often report experiencing several common menopausal symptoms. (Menopause)

A phase III trial of the investigational type 2 diabetes agent ORMD-0801 missed its primary endpoint, with the oral drug failing to significantly reduce HbA1c by 26 weeks versus placebo, said developer Oramed Pharmaceuticals.

Freshwater fish in the U.S. carry extremely high levels of perfluorooctane sulfonic acid, an endocrine-disrupting "forever chemical." (Environmental Research)

Among people with mild hyperparathyroidism, undergoing parathyroidectomy didn't impact fracture risk a decade later. (Journal of Bone and Mineral Research)

Serum levels of the nutrients vitamin B6, vitamin B12, and especially folate were inversely associated with the onset of metabolic syndrome in young adults. (JAMA Network Open)

Comment